NICE has now recommended AstraZeneca and Daiichi Sankyo’s Enhertu for routine NHS use in HER2-low advanced or metastatic breast cancer after a new commercial agreement, opening access to about 1,000 patients a year. The reversal follows repeated cost-effectiveness rejections despite Phase III DESTINY-Breast04 data showing progression-free survival of 10.1 months with trastuzumab deruxtecan versus roughly half that with chemotherapy, and overall survival of 23.9 months versus 17.5 months.

Why It Matters To Oncology

• Enhertu’s approval gives NHS patients with HER2-low disease access to a high-profile antibody-drug conjugate that has already reshaped biomarker-defined breast cancer treatment.

• The decision underscores how pricing frameworks and severity classifications can be as pivotal as clinical efficacy in determining real-world uptake of oncology drugs.

• For drug discovery teams, it is another reminder that ADC innovation alone is not enough; reimbursement strategy and health-economics positioning can decide whether strong survival data translate into broad use.

The Financials

• NICE said the recommendation was enabled by a new commercial agreement with AstraZeneca and Daiichi Sankyo, though financial terms were not disclosed.

• The decision is one of the first major tests of the UK’s higher cost-effectiveness thresholds, raised from £20,000-£30,000 to £25,000-£35,000 per QALY under the 2025 UK-US pharmaceutical deal.

• Enhertu had previously stalled because NICE concluded the offered price did not make the drug sufficiently cost-effective for routine NHS reimbursement in this population.

What They're Saying

• Anne Rigg, NHS England’s national specialty adviser for chemotherapy, called the move “hugely positive news” for women with secondary breast cancer who will now be offered the life-extending treatment on the NHS.

• NICE framed the decision as a product of both the revised commercial terms and its updated assessment environment, including a newer method for evaluating health-related quality of life.

• AstraZeneca CEO Pascal Soriot had previously criticized NICE’s methodology, arguing that labeling advanced HER2-low breast cancer as “moderately severe” hurt the drug’s cost-effectiveness case.

What's Next

• Clinicians should expect routine NHS availability for eligible HER2-low advanced or metastatic patients in England, bringing policy closer to Scotland, where Enhertu has been available since 2023.

• Oncology stakeholders will be watching whether the higher QALY thresholds and revised quality-of-life methods unlock additional previously rejected cancer medicines.

• The case may become a reference point for future ADC launches, especially as developers weigh how to align pivotal trial design, label expansion, and pricing negotiations in biomarker-selected populations.